Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalEndocrinologyType 1 DiabetesTrial Update

Study on Sleep Regularity's Impact on Glycemic Control in Type 1 Diabetes

This study could redefine therapeutic strategies in managing type 1 diabetes by emphasizing the role of sleep regularity in glycemic control and cardiovascular risk. As the findings may lead to novel interventions, pharma companies should stay informed to adapt their portfolios accordingly.

Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Endocrinology / Type 1 Diabetes
Asset: Study
Trial SummaryCLN

Phase III

Endocrinology / Type 1 Diabetes

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This study could redefine therapeutic strategies in managing type 1 diabetes by emphasizing the role of sleep regularity in glycemic control and cardiovascular risk. As the findings may lead to novel interventions, pharma companies should stay informed to adapt their portfolios accordingly.

Why it matters

This study could redefine therapeutic strategies in managing type 1 diabetes by emphasizing the role of sleep regularity in glycemic control and cardiovascular risk. As the findings may lead to novel interventions, pharma companies should stay informed to adapt their portfolios accordingly.

What changed

Trial Update

Analysis

A mechanistic study will explore how improving sleep regularity affects glycemic control and cardiovascular risk in individuals with type 1 diabetes.

This study could redefine therapeutic strategies in managing type 1 diabetes by emphasizing the role of sleep regularity in glycemic control and cardiovascular risk. As the findings may lead to novel interventions, pharma companies should stay informed to adapt their portfolios accordingly.

Monitor results from this study for insights into sleep interventions and their effects on cardiovascular outcomes in type 1 diabetes.

Related companies & assets

Assets

  • Study →

Sources & Humanexa intelligence

Source links

  • Study on Sleep Regularity's Impact on Glycemic Control in Type 1 Diabetes ↗

Related Humanexa pages

  • Study on Sleep Regularity's Impact on Glycemic Control in Type 1 Diabetes →

Related signals

Trial SummaryCLN

Phase III

Gastroenterology / Ulcerative Colitis

Status

Active

Sponsor

Eli Lilly

Signal Score

8.2

Clinicalhigh signal

Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway

A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

Neurology / Multiple System Atrophy

Status

Active

Sponsor

Teva

Signal Score

8.2

Clinicalhigh signal

Teva's TEV-56286 Trial for Multiple System Atrophy Underway

Teva is conducting a trial to evaluate the efficacy and safety of TEV-56286 in adults with Multiple System Atrophy.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.